Question of the Week - January 30th
Ertugliflozin (Steglatro) is a newly approved SGLT-2 Inhibitor. Teaching points for patients include which of the following?
a. This medication frequently causes nausea
b. Only take this medication on empty stomach
c. Expect decreased urination
d. Report any signs of DKA immediately
This form was created inside of Diabetes Educational Services.
Terms of Service